BiomX (NYSEAMERICAN:PHGE) Stock Price Up 1.5% – Still a Buy?

BiomX Inc. (NYSEAMERICAN:PHGE) was up 1.5% during trading on Thursday . The stock traded as high as $0.2825 and last traded at $0.28. 30,150,275 shares were traded during mid-day trading, an increase of 676% from the average daily volume of 3,883,265 shares. The stock had previously closed at $0.2758.

BiomX Trading Down 17.1%

The firm has a 50-day moving average of $0.64 and a 200 day moving average of $2.74. The stock has a market capitalization of $2.74 million, a price-to-earnings ratio of -0.07 and a beta of 1.30.

BiomX (NYSEAMERICAN:PHGE) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $7.38 EPS for the quarter. Equities research analysts predict that BiomX Inc. will post -5.85 EPS for the current fiscal year.

Hedge Funds Weigh In On BiomX

A hedge fund recently bought a new position in BiomX stock. Citadel Advisors LLC bought a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX as of its most recent SEC filing. Hedge funds and other institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.